EVER(Epidermodysplasia Verruciformis Levandowsky-Lutz)/TMC(TransMembral Channel Like Protein) Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients

This study is currently recruiting participants.
Verified September 2013 by University Hospital, Basel, Switzerland
Sponsor:
Information provided by (Responsible Party):
Andreas Arnold, University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT01942005
First received: August 7, 2013
Last updated: September 9, 2013
Last verified: September 2013

August 7, 2013
September 9, 2013
January 2010
December 2015   (final data collection date for primary outcome measure)
Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen. [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01942005 on ClinicalTrials.gov Archive Site
correlation between possibly detected mutation/specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen and a composite of kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression. [ Time Frame: 7 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
EVER(Epidermodysplasia Verruciformis Levandowsky-Lutz)/TMC(TransMembral Channel Like Protein) Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients
EVER/TMC Mutation as Marker of the Risk of Cutaneous Carcinoma in Immunosuppressed Patients,Especially Patients After Organ Transplantation and Patients With HIV Infection

Detection of mutation / specific polymorphism of the EVER/TMC6 and/or EVER/TMC8 gen.

correlation between possibly detected mutation/specific polymorphism and kind and number of neoplasm, age of patients, UV burden, duration and kind of immunosuppression.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

patients who underwent organ transplatation or patients who have a HIV infection

  • Immunosuppression
  • Neoplasm
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
377
Not Provided
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • patients in an immunosuppressive condition either by immunosuppressants or by HIV infection

Exclusion Criteria:

  • written informed consent not given
Both
18 Years and older
No
Contact: Andreas Arnold, MD +41 61 328 67 69 andreas.arnold@usb.ch
Switzerland
 
NCT01942005
11/10
No
Andreas Arnold, University Hospital, Basel, Switzerland
Andreas Arnold
Not Provided
Principal Investigator: Andreas Arnold, MD University Hospital Basel, Dermatology, CH-4031 Basel
University Hospital, Basel, Switzerland
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP